| Description of Property | Date Acquired | Cost or Other Basis | Prior Years' Depreciation | Computation Method | Rate / Life (# of years) |
Current Year's Depreciation Expense | Net Investment Income | Adjusted Net Income | Cost of Goods Sold Not Included |
|---|
| Name of Bond | End of Year Book Value | End of Year Fair Market Value |
|---|---|---|
| VERTEX ENERGY INC BOND - 6.250 | 3,240,000 | 3,783,888 |
| Name of Stock | End of Year Book Value | End of Year Fair Market Value |
|---|---|---|
| AKOUSTIS TECHNOLOGIES INC | 36,514 | 26,052 |
| ALDEYRA THERAPEUTICS INC | 1,326,663 | 680,000 |
| ALIMERA SCIENCES INC | 52,871 | 54,891 |
| ALPINE IMMUNE SCIENCES | 474,808 | 1,837,009 |
| ALTO INGREDIENTS INC | 587,984 | 591,236 |
| APOLLO ENDOSURGERY | 219,293 | 1,778,418 |
| APTOSE BIOSCIENCE | 23,509 | 12,825 |
| AYTU BIOPHARMA INC | 679,719 | 186,743 |
| BEYOND AIR | 9,492 | 9,846 |
| CELCUITY ORD SHS | 10,408 | 10,552 |
| CELLECTAR BIOSCIENCES INC | 11,504 | 8,632 |
| CIDARA THERAPEUTICS INC | 110,769 | 61,629 |
| CLEARPOINT NEURO INC | 36,218 | 33,660 |
| CLEARSIDE BIOMEDICAL INC | 14,190 | 6,182 |
| COGENT INC | 15,509 | 21,021 |
| COHU INC | 249,300 | 300,911 |
| DIAMEDICA THERAPEUTICS INC | 363,553 | 249,365 |
| DIAMEDICA THERAPEUTICS INC - C | 1,509,200 | 1,436,050 |
| ELEDON PHARMACEUTICALS ORD SHS | 68,015 | 70,560 |
| EMCORE CORPORATION | 187,459 | 186,534 |
| EVAXION BIOTECH ADR | 24,839 | 22,100 |
| F-STAR THERAPEUTICS INC | 22,203 | 21,034 |
| FENNEC PHARMACEUTICALS INC | 34 | 22 |
| GAIN THERAPEUTICS ORD SHS | 749,999 | 1,207,741 |
| GIGA-TRONICS INC - WARRANT | 749,999 | 810,175 |
| HTG MOLECULAR DIAGNOSTICS CNV | 400,020 | 244,984 |
| HTG MOLECULAR DIAGNOSTICS INC | 207,953 | 263,911 |
| ICAD INC. | 26,863 | 18,000 |
| IDEAL POWER ORD SHS | 178,875 | 150,750 |
| LAKELAND INDUSTRIES, INC. | 45,510 | 52,471 |
| LIFE TECHNOLOGIES CORP | 979,256 | 918,392 |
| LIQTECH INTERNATIONAL INC | 2,101,051 | 2,280,804 |
| MEDIWOUND | 12,434 | 7,297 |
| MEI PHARMA INC | 195,000 | 200,250 |
| MIROMATRIX MED INC | 2,024,279 | 1,054,875 |
| MOLECULAR TEMPLATES INC | 1,740,645 | 611,465 |
| NUVVE HOLDING CORP WARRANTS | ||
| NUVVE HOLDING ORD SHS | 343,790 | 406,566 |
| OMNIQ CORP COMMON | 788,914 | 653,108 |
| ORYZON GENOMICS | 97,840 | 99,656 |
| PERFORMANT FINANCIAL | 147,336 | 91,098 |
| PLUG POWER INC | 1,465 | 14,115 |
| QUICKLOGIC | 47,583 | 48,954 |
| RECRO PHARMA INC | 30,758 | 24,908 |
| RELMADA THERAPEUTICS | 9,862 | 11,265 |
| RENEO PHARMACEUTICALS ORD SHS | 42,757 | 58,422 |
| REPRO MEDSYSTEMS INC | 85,818 | 87,288 |
| RESTORBIO RTS | ||
| RIMINI STR INC | 6,276 | 5,570 |
| SCIENTIFIC INDUSTRIES | 19,114 | 22,800 |
| SCIENTIFIC INDUSTRIES, INC - C | 907,526 | 917,078 |
| SCIENTIFIC INDUSTRIES, INC - W | 114,634 | |
| SEELOS THERAPEUTICS INC | 16,200 | 16,300 |
| SPECTRA7 MICROSYSTEMS INC | 2,006,400 | 3,579,922 |
| UROGEN PHARMA LTD | 247,135 | 203,628 |
| VALLON PHARMACEUTICALS INC | 27,411 | 28,088 |
| VASCULAR BIOGENICS LTD | 10,690 | 8,774 |
| VERTTEX ENERGY, INC | 4,055,919 | 2,659,521 |
| VIRACTA THERAPEUTICS | 46,779 | 28,061 |
| WESTPORT INNOVATIONS INC | 17,216 | 16,590 |
| X4 PHARMACEUTICALS | 2,364,393 | 646,238 |
| Category/ Item | Listed at Cost or FMV | Book Value | End of Year Fair Market Value |
|---|---|---|---|
| LIFESCI VENTURE SPV XIII LLC | 606,663 | 606,662 | |
| LIQTECH INTL INC - (PRE-FUNDED | 2,969,300 | 3,382,500 | |
| MAXONA PHARMACEUTICALS, INC. P | 1,000,000 | 800,000 | |
| OMEGA THERAPEUTICS, INC PFD SE | 999,999 | 800,000 |
| Description | Revenue and Expenses per Books | Net Investment Income | Adjusted Net Income | Disbursements for Charitable Purposes |
|---|---|---|---|---|
| Administrative Fees | 136,749 | 136,749 | ||
| Bank Charges | 1,477 | 1,477 | ||
| K-1 Exp LIFESCI VENTURE SPV XI | 5,337 | 5,337 | ||
| State or Local Filing Fees | 25 | 25 |
| Description | Revenue And Expenses Per Books | Net Investment Income | Adjusted Net Income |
|---|---|---|---|
| Federal Tax Refund | 690 | ||
| Foreign Currency Loss | -10,194 | -10,194 | |
| Interest Income from Notes | 57,500 | 57,500 |
| Borrower's Name | Relationship to Insider | Original Amount of Loan | Balance Due | Date of Note | Maturity Date | Repayment Terms | Interest Rate | Security Provided by Borrower | Purpose of Loan | Description of Lender Consideration | Consideration FMV |
|---|---|---|---|---|---|---|---|---|---|---|---|
| CYREN LTD | 1,000,000 | 1,000,000 | 2020-03 | 2024-03 | INT/PRIN DUE SEMI-ANNU&ON MATURITY | 575 % | NONE | INVESTMENT | CASH CASH CASH | 1,000,000 | |
| CIRCULOGENE THERANOSTICS INC | 1,000,000 | 1,000,000 | 2021-03 | 2025-04 | INT&PRIN DUE ANNUALLY&ON MATURITY | 5 % | NONE | INVESTMENT | CASH CASH CASH | 1,000,000 | |
| FRESHREALM LLC | 2,000,000 | 2,000,000 | 2021-07 | 2022-07 | INTEREST AND PRINCIPAL ON MATURITY | 8 % | ALL ASSETS OF THE COMPANY | INVESTMENT | CASH CASH CASH | 2,000,000 |
| Category | Amount | Net Investment Income | Adjusted Net Income | Disbursements for Charitable Purposes |
|---|---|---|---|---|
| Investment Management Services | 6,345 | 6,345 |
| Category | Amount | Net Investment Income | Adjusted Net Income | Disbursements for Charitable Purposes |
|---|---|---|---|---|
| 990-PF Estimated Tax for 2021 | 202,700 | |||
| 990-PF Extension for 2020 | 29,120 |